Baxalta (Baxalta) ROE % Adjusted to Book Value : 2.18% (As of Mar. 2016)

View and export this data going back to 2015. Start your Free Trial

What is Baxalta ROE % Adjusted to Book Value?

Baxalta's ROE % for the quarter that ended in Mar. 2016 was 14.24%. Baxalta's PB Ratio for the quarter that ended in Mar. 2016 was 6.54. Baxalta's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2016 was 2.18%.

Baxalta ROE % Adjusted to Book Value Historical Data

The historical data trend for Baxalta's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxalta ROE % Adjusted to Book Value Chart

Baxalta Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

ROE % Adjusted to Book Value

2.92

Baxalta Quarterly Data
	Dec12	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
ROE % Adjusted to Book Value	Get a 7-Day Free Trial						-	3.83	5.97	1.42	2.18

Competitive Comparison of Baxalta's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Baxalta's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baxalta's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baxalta's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Baxalta's ROE % Adjusted to Book Value falls into.

Baxalta ROE % Adjusted to Book Value Calculation

Baxalta's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2015 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	19.77%	/	6.76
	=	2.92%

Baxalta's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2016 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	14.24%	/	6.54
	=	2.18%

Baxalta ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Baxalta's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxalta (Baxalta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baxalta Inc (NYSE:BXLT) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.baxalta.com

Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.

Executives

Gail D Fosler	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
John Glasspool	officer: See Remarks	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Dagmar Rosa-bjorkeson	officer: EVP and President, Biosimilars	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
David D. Meek	officer: EVP and President, Oncology	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Karen Jean Ferrante	director	150 ADIRONDACK DRIVE, EAST GREENWICH RI 02818
Peter G Edwards	officer: SVP and General Counsel	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Robert J. Hombach	officer: EVP. CFO and COO	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Blake E Devitt	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Wayne T Hockmeyer	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Anne-marie Law	officer: EVP & Head of Human Resources	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Stroucken Albert P L	director	BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Gavin James R Iii	director	BAXTER INTERNATIONAL INC, ONE BAXTER PARKWAY, DEERFIELD IL 60015
John D Forsyth	director	C/O BAXTER INTERNATIONAL, ONE BAXTER PARKWAY, DEERFIELD IL 60015
Ludwig Hantson	director, officer: President and CEO	C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Francois Nader	director	550 HILLS DRIVE, BEDMINSTER NJ 07921